Investigation into adamantane-based M2 inhibitors with FB-QSAR

Medicinal Chemistry

Volumn 5, Issue 4, 2009, Pages 305-317

  Wei, Hang ^a   Wang, Cheng Hua ^b   Du, Qi Shi ^a,d   Meng, Jianzong ^a,c   Chou, Kuo Chen ^d  

^a GUANGXI UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

^c Nanning Fermentation and Enzyme Engineering Research and Technique Center   (China)

^d GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

Amantadine; Drug design; FB QSAR; Influenza A; M2 protein; Rimantadine

Indexed keywords

ADAMANTANE; AMANTADINE; PROTEIN INHIBITOR; PROTEIN M2; PROTEIN M2 INHIBITOR; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; INFLUENZA VIRUS A; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 67650073942     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609788681430     Document Type: Article

References (58)

1. Ferguson, N.M.; Cummings, D.A.; Cauchemez, S.; Fraser, C.; Riley, S.; Meeyai, A.; Iamsirithaworn, S.; Burke, D. S. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature, 2005, 437, 209-214.
2. Wei, D.Q.; Du, Q.S.; Sun, H.; Chou, K. C. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem. Biophys. Res. Comm., 2006, 344, 1048-1055.
3. Wang, S.Q.; Du, Q.S.; Chou, K. C. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem. Biophys. Res. Comm., 2007, 354, 634-640.
4. Du, Q.S.; Wang, S.Q.; Chou, K. C. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem. Biophys. Res. Comm., 2007, 362, 525-531.
5. Lew, W.; Chen, X.; Kim, C. U. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem., 2000, 7, 663-672.
6. Dunn, C.J.; Goa, K. L. Zanamivir: a review of its use in influenza. Drugs, 1999, 58, 761-784.
7. Kolocouris, N.; Zoidis, G.; Foscolos, G.B.; Fytas, G.; Prathalingham, S.R.; Kelly, J.M.; Naesens, L.; De Clercq, E. Design and synthesis of bioactive adamantane spiro heterocycles. Bioorg. Med. Chem. Lett., 2007, 17, 4358-4362.
8. Stamatiou, G.; Kolocouris, A.; Kolocouris, N.; Fytas, G.; Foscolos, G.B.; Neyts, J.; De Clercq, E. Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups. Bioorg. Med. Chem. Lett., 2001, 11, 2137-2142.
9. Schnell, J.R.; Chou, J. J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature, 2008, 451, 591-595.
10. Hay, A.J.; Wolstenholme, A.J.; Skehel, J.J.; Smith, M. H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J., 1985, 4, 3021-3024.
11. Wang, C.; Takeuchi, K.; Pinto, L.H.; Lamb, R. A. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol., 1993, 67, 5585-5594.
12. Deyde, V.M.; Xu, X.; Bright, R.A.; Shaw, M.; Smith, C.B.; Zhang, Y.; Shu, Y.; Gubareva, L.V.; Cox, N.J.; Klimov, A. I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis., 2007, 196, 249-257.
13. Huang, R.B.; Du, Q.S.; Wang, C.H.; Chou, K. C. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem. Biophys. Res. Comm., 2008, 377, 1243-1247.
14. Chou, K. C. Review: structural bioinformatics and its impact to biomedical science. Curr. Med. Chem., 2004, 11, 2105-2134.
15. Chou, K. C. Modelling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5. Biochem. Biophys. Res. Commun., 2004, 316, 636-642.
16. Chou, K. C. Molecular therapeutic target for type-2 diabetes. J. Proteome Res., 2004, 3, 1284-1288.
17. Chou, K. C. Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor. Biochem. Biophys. Res. Commun., 2004, 319, 433-438.
18. Chou, K. C. Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. J. Proteome Res., 2005, 4, 1681-1686.
19. Chou, K.C.; Wei, D.Q.; Zhong, W. Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. (Erratum: ibid., 2003, Vol.310, 675). Biochem. Biophys. Res. Comm., 2003, 308, 148-151.
20. Li, Y.; Wei, D.Q.; Gao, W.N.; Gao, H.; Liu, B.N.; Huang, C.J.; Xu, W.R.; Liu, D.K.; Chen, H.F.; Chou, K. C. Computational approach to drug design for oxazolidinones as antibacterial agents. Med. Chem., 2007, 3, 576-582.
21. Wang, J.F.; Wei, D.Q.; Chen, C.; Li, Y.; Chou, K. C. Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept. Lett., 2008, 15, 27-32.
22. Zhang, R.; Wei, D.Q.; Du, Q.S.; Chou, K. C. Molecular modeling studies of peptide drug candidates against SARS. Med. Chem., 2006, 2, 309-314.
23. Gao, W.N.; Wei, D.Q.; Li, Y.; Gao, H.; Xu, W.R.; Li, A.X.; Chou, K. C. Agaritine and its derivatives are potential inhibitors against HIV proteases. Med. Chem., 2007, 3, 221-226.
24. Zheng, H.; Wei, D.Q.; Zhang, R.; Wang, C.; Wei, H.; Chou, K. C. Screening for New Agonists against Alzheimer's Disease. Med. Chem., 2007, 3, 488-493.
25. Chou, K.C.; Nemethy, G.; Scheraga, H. A. Energetic approach to packing of a-helices: 2. General treatment of nonequivalent and nonregular helices. J. Am. Chem. Soc., 1984, 106, 3161-3170.
26. Chou, K.C.; Maggiora, G.M.; Nemethy, G.; Scheraga, H. A. Energetics of the structure of the four-alpha-helix bundle in proteins. Proc. Nat. Acad. Sci. USA, 1988, 85, 4295-4299.
27. Sirois, S.; Wei, D.Q.; Du, Q.S.; Chou, K. C. Virtual Screening for SARS-CoV Protease Based on KZ7088 Pharmacophore Points. J. Chem. Inf. Comput. Sci., 2004, 44, 1111-1122.
28. Chou, K.C.; Wei, D.Q.; Du, Q.S.; Sirois, S.; Zhong, W. Z. Review: Progress in computational approach to drug development against SARS. Curr. Med. Chem., 2006, 13, 3263-3270.
29. Chou, K. C. Energy-optimized structure of antifreeze protein and its binding mechanism. J. Mol. Biol., 1992, 223, 509-517.
30. Chou, K.C.; Shen, H. B. Cell-PLoc: A package of web-servers for predicting subcellular localization of proteins in various organisms. Nat. Protoc., 2008, 3, 153-162.
31. Chou, K.C.; Shen, H. B. Review: Recent progresses in protein subcellular location prediction. Anal. Biochem., 2007, 370, 1-16.
32. Chou, K.C.; Shen, H. B. MemType-2L: A Web server for predicting membrane proteins and their types by incorporating evolution information through Pse-PSSM. Biochem. Biophys. Res. Commun., 2007, 360, 339-345.
33. Shen, H.B.; Chou, K. C. EzyPred: A top-down approach for predicting enzyme functional classes and subclasses. Biochem. Biophys. Res. Commun., 2007, 364, 53-59.
34. Chou, K. C. Prediction of G-protein-coupled receptor classes. J. Proteome Res., 2005, 4, 1413-1418.
35. Xiao, X.; Wang, P.; Chou, K. C. GPCR-CA: A cellular automaton image approach for predicting G-protein-coupled receptor functional classes. J. Comput. Chem., 2008, DOI 10.1002/jcc.21163.
36. Chou, K.C.; Shen, H. B. ProtIdent: a web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem. Biophys. Res. Comm., 2008, 376, 321-325.
37. Shen, H.B.; Chou, K. C. Identification of proteases and their types. Anal. Biochem., 2009, 385, 153-160.
38. Chou, K. C. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J. Biol. Chem., 1993, 268, 16938-16948.
39. Chou, K. C. Review: Prediction of HIV protease cleavage sites in proteins. Anal. Biochem., 1996, 233, 1-14.
40. Shen, H.B.; Chou, K. C. HIVcleave: a web-server for predicting HIV protease cleavage sites in proteins. Anal. Biochem., 2008, 375, 388-390.
41. Chou, K.C.; Shen, H. B. Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem. Biophys. Res. Commun., 2007, 357, 633-640.
42. Shen, H.B.; Chou, K. C. Signal-3L: a 3-layer approach for predicting signal peptide. Biochem. Biophys. Res. Commun., 2007, 363, 297-303.
43. Du, Q.S.; Huang, R.B.; Chou, K. C. Review: recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Pept. Sci., 2008, 9, 248-259.
44. Du, Q.S.; Mezey, P.G.; Chou, K. C. Heuristic Molecular Lipophilicity Potential (HMLP): A 2D-QSAR Study to LADH of Molecular Family Pyrazole and Derivatives. J. Comput. Chem., 2005, 26, 461-470.
45. Du, Q.S.; Huang, R.B.; Wei, Y.T.; Du, L.Q.; Chou, K. C. Multiple Field Three Dimensional Quantitative Structure-Activity Relationship (MF-3D-QSAR). J. Comput. Chem., 2008, 29, 211-219.
46. Du, Q.S.; Huang, R.B.; Wei, Y.T.; Pang, Z.W.; Du, L.Q.; Chou, K. C. Fragment-Based Quantitative Structure-Activity Relationship (FB-QSAR) for Fragment-Based Drug Design. J. Comput. Chem., 2009, 30, 295-304.
47. Prado-Prado, F.J.; Gonzalez-Diaz, H.; de la Vega, O.M.; Ubeira, F.M.; Chou, K. C. Unified QSAR approach to antimicrobials. Part 3: First multi-tasking QSAR model for Input-Coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg. Med. Chem., 2008, 16, 5871-5880.
48. Dea-Ayuela, M.A.; Perez-Castillo, Y.; Meneses-Marcel, A.; Ubeira, F.M.; Bolas-Fernandez, F.; Chou, K.C.; Gonzalez-Diaz, H. HP-Lattice QSAR for dynein proteins: Experimental proteomics (2D-electrophoresis, mass spectrometry) and theoretic study of a Leishmania infantum sequence. Bioorg. Med. Chem., 2008, 16, 7770-7776.
49. Cruz-Monteagudo, M.; Munteanu, C.R.; Borges, F.; Natália, M.; Cordeiro, D.S.; Uriarte, E.; Chou, K.C.; Gonzalez-Diaz, H. Stochastic molecular descriptors for polymers. 4. Study of complex mixtures with topological indices of mass spectra spiral and star networks: the blood proteome case. Polymer, 2008, 49, 5575-5587.
50. Aguero-Chapin, G.; Antunes, A.; Ubeira, F.M.; Chou, K.C.; Gonzalez-Diaz, H. Comparative study of topological indices of macro/supra-molecular RNA complex networks. J. Chem. Inf. Mod., 2008, 48, 2265-2277.
51. Gonzalez-Diaz, H.; Gonzalez-Diaz, Y.; Santana, L.; Ubeira, F.M.; Uriarte, E. Proteomics, networks, and connectivity indices. Proteomics, 2008, 8, 750-778.
52. Tataridis, D.; Fytas, G.; Kolocouris, A.; Fytas, C.; Kolocouris, N.; Foscolos, G.B.; Padalko, E.; Neyts, J.; De Clercq, E. Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A. Bioorg. Med. Chem. Lett., 2007, 17, 692-696.
53. Kolocouris, A.; Tataridis, D.; Fytas, G.; Mavromoustakos, T.; Foscolos, G.B.; Kolocouris, N.; De Clercq, E. Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling. Bioorg. Med. Chem. Lett., 1999, 9, 3465-3470.
54. Wang, T.; Yang, J.; Shen, H.B.; Chou, K. C. Predicting membrane protein types by the LLDA algorithm. Protein Pept. Lett., 2008, 15, 915-921.
55. Hansch, C. M.R.M.; Fujita, T.; Maloney, P.P.; Geiger, F.; Streich, M. The correlation of biological activity of plant growth regulators and chloromycetin derivatives with Hammett constants and partition coefficients. J. Am. Chem. Soc., 1963, 85, 2817-2824.
56. Free, S. M., Jr.; Wilson, J. W. A mathematical contribution to structure-activity studies. J. Med. Chem., 1964, 7, 395-399.
57. Chou, K.C.; Zhang, C. T. Review: Prediction of protein structural classes. Crit. Rev. Biochem. Mol. Biol., 1995, 30, 275-349.
58. Chou, K. C. A key driving force in determination of protein structural classes. Biochem. Biophys. Res. Commun., 1999, 264, 216-224.